Clinical Trial Update: Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the addition of pembrolizumab to Radium-223 in metastatic castration-resistant prostate cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-07-20